Identification of nonproliferating but viable hypoxic tumor cells in vivo
- PMID: 9721858
Identification of nonproliferating but viable hypoxic tumor cells in vivo
Abstract
We have used the combination of pimonidazole labeling of hypoxic cells, bromodeoxyuridine labeling of proliferating cells, and cell sorting based on Hoechst 33342 perfusion to directly study hypoxia and proliferation in human tumor xenografts and transplantable murine tumors in vivo. Hypoxia was largely confined to cells in regions with the least perfusion, although in tumors exhibiting transient blood flow, hypoxic cells were not as highly localized. Similarly, proliferation and hypoxia were mutually exclusive except in areas of a tumor subjected to transient changes in perfusion. By determining the clonogenic potential, pimonidazole labeling intensity, and radiosensitivity of sorted tumor cell subpopulations, we have provided direct evidence that pimonidazole identifies hypoxic tumor cells of therapeutic relevance in vivo. Given that pimonidazole exhibits few diffusion or delivery problems and no apparent cytotoxicity, it appears to be a versatile and useful label for hypoxic cells in solid tumors.
Similar articles
-
Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia.Br J Cancer. 2000 Dec;83(11):1525-31. doi: 10.1054/bjoc.2000.1489. Br J Cancer. 2000. PMID: 11076663 Free PMC article.
-
The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy.Radiother Oncol. 2006 Aug;80(2):138-42. doi: 10.1016/j.radonc.2006.07.022. Epub 2006 Aug 17. Radiother Oncol. 2006. PMID: 16916562 Clinical Trial.
-
Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas.Oral Oncol. 2008 Apr;44(4):335-44. doi: 10.1016/j.oraloncology.2007.04.004. Epub 2007 Aug 6. Oral Oncol. 2008. PMID: 17689286
-
Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.Anticancer Drug Des. 1998 Sep;13(6):703-30. Anticancer Drug Des. 1998. PMID: 9755726 Review.
-
Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.Bull Cancer. 2008 Mar;95(3):282-91. doi: 10.1684/bdc.2008.0592. Bull Cancer. 2008. PMID: 18390408 Review.
Cited by
-
Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours.Nat Cell Biol. 2018 Jul;20(7):775-781. doi: 10.1038/s41556-018-0118-z. Epub 2018 Jun 25. Nat Cell Biol. 2018. PMID: 29941933 Free PMC article.
-
Hypoxia in microscopic tumors.Cancer Lett. 2008 Jun 18;264(2):172-80. doi: 10.1016/j.canlet.2008.02.037. Epub 2008 Apr 1. Cancer Lett. 2008. PMID: 18384940 Free PMC article. Review.
-
Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.Radiat Res. 2015 May;183(5):487-96. doi: 10.1667/RR13959.1. Epub 2015 May 4. Radiat Res. 2015. PMID: 25938770 Free PMC article. Review.
-
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.Invest New Drugs. 2006 Jan;24(1):27-36. doi: 10.1007/s10637-005-4540-2. Invest New Drugs. 2006. PMID: 16379040
-
The tumor microenvironment and metastatic disease.Clin Exp Metastasis. 2009;26(1):19-34. doi: 10.1007/s10585-008-9182-2. Epub 2008 Jun 10. Clin Exp Metastasis. 2009. PMID: 18543068 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical